Study cites factors of success, failure for hips with dysplasia vs FAI after arthroscopy
Click Here to Manage Email Alerts
Recently published data indicated that after arthroscopic management, dysplastic hips had inferior good/excellent results with higher rates of failure than hips with femoroacetabular impingement.
Researchers retrospectively reviewed the records of 77 patients who underwent an all-arthroscopic approach for treatment of dysplastic hip deformities. Investigators also analyzed 215 age-matched patients who were treated arthroscopically for femoroacetabular impingement (FAI) without hip dysplasia. Mean follow-up for the dysplastic hips was 26 months after arthroscopy vs. 22.7 months for the FAI group. Investigators evaluated patients using a modified Harris Hip score (mHHS), SF-36 and VAS for pain. They also recorded revision surgeries and complications.
Results showed the mean lateral center-edge angle was 20.8°. Investigators also found a mean Tönnis angle of 11°. The mHHS improved from 65 preoperatively to 81.3 at final follow-up in the dysplastic cohort. In the FAI group, these values improved from 24.4 to 88.4, respectively. Investigators noted good/excellent results in 60.9% of the dysplastic hips. Using a mHHS of at least 70, osteotomy or hip arthroplasty to define failure, investigators found a failure rate of 32.2% for that group. In comparison, researchers found 81.2% of the FAI hips had good/excellent results and 10.5% failed during the final follow-up.
In the dysplastic hips, lower scores correlated with Grade 4 chondral defects and patients who had capsular plication and labral repair had better results and lower failure rates. At the follow-up, microfracture approached significance for lower mHHS in both groups. No iatrogenic subluxations or dislocations were reported during the follow-up. ‒ by Monica Jaramillo
Disclosures: Larson is a consultant for A3 Surgical and Smith & Nephew, and also has stock options in A3 Surgical. Please see the full study for a list of all other authors’ relevant financial disclosures.